ReviewExpert review of anticancer therapy2022
Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Review in Expert review of anticancer therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Genome-Wide Meta-Analysis Identifies Five Single-Nucleotide Polymorphisms Associated With Both Vitiligo and Freckles in the Chinese Han Population.Journal of cosmetic dermatology · 2025Pooled it
- Efficacy and Safety of Tebentafusp in Uveal Melanoma: A Systematic Review and Single-Arm Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific.Cell reports. Medicine · 2025Trial
- Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma.Journal for immunotherapy of cancer · 2024Trial
- Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases.Cardiovascular and interventional radiology · 2026Article
- Circulating tumor DNA accelerates diagnosis and treatment guidance for metastatic uveal melanoma with hepatic lesions not amenable to biopsy.Melanoma research · 2026Article
- A CRISPR-Cas13d cancer therapeutic enables selective elimination of uveal melanoma.Molecular therapy. Oncology · 2026Article
- Artificial intelligence-assisted assessment of metabolic response to tebentafusp in metastatic uveal melanoma: a long axial field-of-view [European journal of nuclear medicine and molecular imaging · 2026Article
- Bispecific T-Cell Engagers, Cell Therapies, and Other Non-Checkpoint Immunotherapies for Metastatic Uveal Melanoma: A Narrative Review.Journal of clinical medicine · 2026Review
- Integrated Transcriptomic Analysis Identifies Immune Remodeling and Prognostic Signatures in Uveal Melanoma.International journal of genomics · 2026Article
- Article
- Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases.Cancer metastasis reviews · 2025Review
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.Antibodies (Basel, Switzerland) · 2025Review
- Targeting IL13Rα2 in melanoma with a bispecific T-cell engager: expression profiling and preclinical evaluation.Journal for immunotherapy of cancer · 2025Article
- A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma.Journal of clinical medicine · 2025Review
- A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1cFrontiers in immunology · 2025Article
- Review
- Uveal melanoma: Recent advances in immunotherapy.World journal of clinical oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionMetastatic uveal melanoma is associated with poor prognosis and few treatment options. Tebentafusp recently became the first FDA-approved agent for metastatic uveal melanoma. AREAS COVERED: In this review, we describe the mechanism of action of tebentafusp as well as preclinical data showing high tumor specificity of the drug. We also review promising early-phase trials in which tebentafusp demonstrated activity in metastatic uveal melanoma patients with an acceptable toxicity profile that included cytokine-mediated, dermatologic-related, and liver-related adverse events. Finally, we summarize findings from a pivotal phase III randomized trial in which tebentafusp demonstrated significant improvement in overall survival in comparison with investigator choice therapy. EXPERT OPINION: Tebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the preferred frontline agent for most HLA-A*0201 positive patients. However, patients with rapidly progressing disease or high tumor benefit may not derive the same benefit. Areas of future study should focus on its role in the adjuvant setting as well as strategies to improve the efficacy of tebentafusp in the metastatic setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.